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Mechanisms and treatment of cardiovascular
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Department of Pediatrics, Washington University School of Medicine/St. Louis Children’s Hospital, St. Louis, Missouri, USA.
3Departments of Pediatrics and Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.

Williams-Beuren syndrome (WBS) is a microdeletion disorder caused by heterozygous loss of
approximately 1.5-Mb pairs of DNA from chromosome 7. Patients with WBS have a characteristic constellation of medical and cognitive findings, with a hallmark feature of generalized
arteriopathy presenting as stenoses of elastic arteries and hypertension. Human and mouse
studies establish that defects in the elastin gene, leading to elastin haploinsufficiency, underlie
the arteriopathy. In this review we describe potential links between elastin expression and arteriopathy, possible explanations for disease variability, and current treatment options and their
limitations, and we propose several new directions for the development of nonsurgical preventative therapies
based on insights from elastin biology.
Williams-Beuren syndrome (WBS, also referred to as Williams
syndrome; OMIM 194050) was first recognized as a clinical syndrome, separate from other developmental disability syndromes,
because of a unique constellation of cardiovascular (CV) abnormalities. In this review, we describe these characteristic abnormalities, the considerable progress that has been made in understanding their etiology and pathophysiology, and new insights
gained into underlying molecular pathways. Finally, we consider
currently available therapeutic approaches and opportunities to
develop new treatment options.
Overview of WBS
In 1961, J.C.P. Williams described four patients and proposed that
“the association of supravalvular stenosis with the physical and
mental characteristics here described may constitute a previously
unrecognized syndrome” (1). Shortly thereafter A.J. Beuren reported eleven new patients (2), and the condition has fittingly borne
the eponym Williams-Beuren syndrome ever since.
WBS affects approximately 1/10,000 individuals, is found worldwide among all racial and ethnic groups, and displays multisystem
medical and nonmedical problems (3–5). In 1993 the genetic cause
of WBS, a chromosomal microdeletion, was reported (6), and this
knowledge permitted development of a laboratory-based diagnostic test, so the diagnosis no longer rests on clinical criteria only.
The most widely used method to confirm the diagnosis has been
FISH, but DNA dosage techniques such as quantitative PCR, multiplex ligation-dependent probe amplification, and chromosomal
microarray, also known as comparative genomic hybridization,
may soon become confirmatory tests of choice.
Non-CV clinical features of WBS. Persons with WBS have a subtle
but distinctive facial appearance that changes with age (Figure
1) (3). Their linear growth is usually smaller than that of siblings
Nonstandard abbreviations used: CV, cardiovascular; EBP, elastin-binding protein;
NAHR, nonallelic homologous recombination; NCF1, neutrophil cytosolic factor 1;
SVAS, supravalvular aortic stenosis; WBS, Williams-Beuren syndrome.
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or healthy, age-matched controls. Though infants and young
children tend to be thin, or even underweight, many WBS adults
are overweight (3, 7, 8).
Endocrine abnormalities are commonly reported and include
hypercalcemia, abnormal glucose metabolism, and (subclinical)
hypothyroidism. The precise frequencies, etiologies, natural histories, and best treatments of these endocrine problems remain
to be determined. Other common findings include dental anomalies (small, abnormally shaped teeth, absent teeth, malocclusion),
gastrointestinal dysmotility (reflux, constipation), diverticular disease, musculoskeletal anomalies (joint stiffness, scoliosis), sensorineural hearing loss, genitourinary anomalies (urinary frequency,
bladder diverticuli), and neurological problems (abnormal tone,
hyperreflexia, and cerebellar findings) (3, 7, 9, 10).
Persons with WBS have intellectual handicaps that generally
meet the definition of mild to moderate mental retardation on
standardized testing. The average full-scale IQ is reported to be
55–60, but a fairly broad range exists, extending from 40–90 (11).
Particularly notable is the pattern of intellectual peaks and valleys,
referred to as the Williams syndrome cognitive profile, with relative
strengths in selected language domains and a prominent weakness
in the visuospatial domain (12). Persons with WBS display characteristic personality and emotional traits. Their generally social
and friendly demeanor coexists with anxiety (especially anticipatory anxiety), phobias, and perseverative tendencies (i.e., repetitive
thoughts or behaviors) (7, 13).
Molecular genetics of WBS. The etiology of WBS, a mystery for more
than 30 years after its initial description, is now known to be a
contiguous gene deletion or microdeletion syndrome at chromosome 7q11.23. Although the chromosomal location is unique, the
mechanism of origin is comparable with that of other microdeletion disorders, namely, a deleted genomic interval resulting from
the presence of low-copy repetitive DNA (duplicons) that predispose to nonallelic homologous recombination (NAHR) (14).
The locus for WBS was found through the study of a phenotypically overlapping disorder. Specifically, disruption of the elastin
(ELN) gene was identified as the cause of the condition known as
familial supravalvular aortic stenosis (familial SVAS) syndrome (OMIM
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Figure 1
Distinctive facial appearance of persons with WBS. Young child with WBS at 15 months (A) and 3 years (B). Note subtle characteristic facial features including wide mouth, full cheeks, long philtrum, small nose, and delicate chin. (C) At left, the same individual depicted in A and B at 21 years
of age. At right, another individual with WBS at 28 years of age. Note persistence of wide mouth, full lips, and delicate chin in adults with WBS.

185500) by application of linkage analysis and gene sequencing,
and by cloning of a chromosome 7q11.2 translocation breakpoint,
in selected familial SVAS kindreds (15, 16). Given similar vascular
pathologies in familial SVAS and in WBS, study of the ELN gene was
undertaken, and deletion of an ELN allele was identified as the cause
of WBS (6). Subsequent characterization of the deleted interval, now
referred to as the WBS critical region (Figure 2), reveals the following
(17–19): (a) 90%–95% of patients clinically diagnosed with WBS have
an approximately 1.55-Mb deletion associated with loss of 26–28
genes; (b) 5%–8% of clinically diagnosed WBS patients have a slightly
larger, approximately 1.84-Mb pair deletion associated with loss of
28 genes; (c) the deleted intervals are flanked by highly homologous
stretches of DNA, organized into a single centromeric duplicon and
two telomeric duplicons; (d) each duplicon contains genes, pseudogenes, and clusters of related genes; (e) the duplicons predispose to
NAHR through intra- or inter-chromosomal exchange during meiosis; and (f) the deletion arises with equal frequency on either the
maternally or the paternally inherited chromosome 7 homolog.
Different breakpoints in the medial block of telomeric repeats
determine whether neutrophil cytosolic factor 1 (NCF1) and
general transcription factor II I repeat domain–containing 2
(GTF2IRD2) are deleted or not. Several of the deleted genes in
patients with WBS are depicted in Figure 2. As this review focuses
on CV aspects of WBS, our discussion will emphasize the ELN
gene and consequences resulting from its functional loss. For a
complete list and description of the genes constituting the WBS
critical region, the reader is directed to ref. 20.
Loss of an ELN allele is the single most important genetic change
responsible for the CV problems of WBS. The ELN gene encodes a
precursor protein, tropoelastin. Multiple isoforms of tropoelastin
are generated via alternative splicing, secreted into the extracellular
matrix, deposited onto a preformed network of fibrillin microfibrils, and are cross-linked by the lysyl oxidase family of enzymes
(21). This process of elastic fiber assembly requires the coordinated expression of multiple genes, and peaks during late fetal and
perinatal stages of development (22).
The most common pathological consequence of chromosome
7q11.23 duplicon–mediated NAHR is WBS (e.g., deletion of the
intervening sequence). However, duplication of the intervenThe Journal of Clinical Investigation

ing sequence (23) has recently been detected by chromosomal
microarray; affected individuals have expressive speech delay
without evidence of WBS features (24). The most common nonpathological consequence of NAHR at this locus is inversion of
the WBS critical region (25). Inversion carriers are asymptomatic,
though they may have a slightly greater risk of meiotic NAHR
producing a gamete, which, when fertilized, results in an offspring with WBS (26).
The chromosome 7q11.23 genomic architecture in the WBS
critical region has genetic synteny on mouse chromosome 5 (27).
The salient differences are the opposite orientation of the region
and the absence of low-copy repeats in the mouse. Such synteny
provides a powerful tool for genotype-phenotype analysis through
the generation and characterization of genetically modified mice;
a complete list of currently published WBS mouse models is
provided in Supplemental Table 1 (supplemental material available online with this article; doi:10.1172/JCI35309DS1). The Eln
knockout mouse model is discussed in considerable detail below.
A CV phenotype has not been appreciated in any other mouse in
which a WBS critical region gene has been genetically altered, such
as Fzd9–/– (28), Limk1–/– (29), Gtf2ird1–/– (30), or Cyln2–/– mice (31).
A complementary approach to elucidating the role of deleted
genes in the WBS phenotype involves detailed characterization
of patients with smaller atypical deletions. These patients, in
whom less than 26 genes have been deleted from the WBS critical
region (Figure 2), are relatively uncommon. Despite their rarity,
such cases can provide valuable information. Characterization of
patients with atypical deletions that variously encompass LIM1K,
GTF2IRD1, and/or GTF2I suggest that loss of one or more of these
genes contributes to the WBS cognitive profile (32–34). Given the
combination of a relatively small number of genes in the WBS
critical region and a remarkably distinct set of features, WBS has
become a “model” disorder for the study of genotype-phenotype
correlations in microdeletion syndromes.
CV clinical features of WBS
CV disease, particularly an arteriopathy consisting of stenoses of
medium- and large-sized arteries, is the hallmark of WBS. In early
case reports and case series, the diagnosis was primarily established
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Figure 2
The WBS critical region. The chromosome 7q11.23
microdeletion, with the loss of 26–28 genes, that is
responsible for WBS. Selected genes are labeled.
Duplicons predispose to NAHR. More than 90%
of WBS patients have the ~1.55-Mb pair deletion
extending from FKBP6 to GTF2I, while approximately 5% have the slightly larger deletion of 1.84Mb pairs. Very rare patients have atypical deletions
smaller than the common deletion. Schematics of
atypical deletions are shown on right and include
a very small deletion encompassing ELN and an
adjacent gene; a typical centromeric breakpoint
but not the common telomeric breakpoint; and a
typical telomeric breakpoint but not the typical centromeric breakpoint. Not all genes are shown; see
ref. 20 for a complete list of genes. WBSCR, WBS
critical region.

by cardiologists evaluating patients for a heart murmur, which
usually was diagnosed as SVAS on cardiac imaging or through
catheterization and/or surgery (1, 35).
The prevalence of CV abnormalities in 423 patients from nine
selected international series published in the last two decades is
shown in Table 1 (36–44). Many patients have multiple CV clinical
findings. Although the vascular stenoses of WBS predominantly
affect the supravalvular aortic (Figure 3) and pulmonary regions,
lesions located elsewhere also occur, primarily but not exclusively
affecting the vascular branch points. The wide range of published
prevalence reflects the age-dependent frequency of clinical features, variable study methods, especially the modality used to
ascertain specific clinical features, and biases in case ascertainment. Spontaneous improvement in pulmonary arterial stenosis
over time has been well established, whereas SVAS may progress
especially in the first five years of life (36, 38–40, 45, 46). Prospective use of echocardiographic dimensions in one study found a
100% frequency of SVAS but only a 3% frequency of pulmonary
arterial stenosis (37). A much higher frequency of pulmonary
arterial stenosis (77%–83%) was found in two series of patients,
all of whom had undergone at least one cardiac catheterization
(36, 39). With improved noninvasive cardiac imaging, valvular
abnormalities, particularly of the mitral valve, are being detected
with increasing frequency (42).
1608
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A small number of patients with SVAS (as part of either WBS or
familial SVAS syndrome) have a diffuse and more severe variant of
arteriopathy, sometimes termed middle aortic syndrome (36, 42, 47).
These patients have stenosis of the thoracic and abdominal aorta,
mesenteric arteries, and renal arteries. Left ventricular hypertrophy
and hypertension are common in this severe form of CV disease.
Clinically important coronary artery lesions (Figure 3) are
reported infrequently but may put the patient at risk of sudden
death. An autopsy series of five patients whose CV disease represented the severe end of the spectrum demonstrated obstructive
coronary disease in all individuals, with vessel wall hyperplasia,
fibrosis, and disorganization (48). In a catheterization study of 26
patients with WBS, coronary artery dilation or stenosis was found
in 27% (39). In mixed cohorts of individuals who had either WBS
or mutations in the ELN gene in conjunction with severe SVAS
requiring surgery, coronary disease was found in 28%–45% (49,
50). Although coronary disease appears to be related to the severity of supravalvular aortic narrowing (39), case reports indicate
that severe coronary artery disease leading to death may be the
sole vascular feature in some patients with WBS (51, 52). Since
the sensitivity of standard non-stress echocardiographic studies
for coronary stenosis in the general population is low, perfusion
imaging techniques may be needed to investigate the significance
of coronary artery disease in WBS (53).

http://www.jci.org

Volume 118

Number 5

May 2008

Downloaded on August 16, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/35309

science in medicine
Table 1
CV clinical findings in patients from nine selected seriesA
Clinical findingB

Combined
prevalence (%)

Range of
prevalence

84
69
34
17
15
4
2
5
3

53–100
28–100
0–83
3–30
4–43
0–19
0–14
0–47
0–11

(%)C
Any CV disease
SVAS
Pulmonary arterial stenosis
Hypertension
Mitral valve disease
Coarctation of aorta
Aortic hypoplasiaD
Pulmonary valve disease
Aortic valve disease
ARefs.

36–44; n = 423. BSome patients had multiple abnormalities.
of prevalence for all series combined. DSevere diffuse hypoplasia, or abdominal coarctation.
CRange

Patients with WBS are at a higher risk of sudden death. Wessel et
al. found a risk of 1/1,000 patient years with five cases of sudden
death, a 25- to 100-fold increase compared with the normal population (54). Death secondary to myocardial infarction has been
detailed in three patients (55, 56). In another report of ten WBS
patients with sudden death, pathologic findings suggest that coronary artery stenosis and severe biventricular outflow tract obstruction are mechanisms for myocardial ischemia and arrhythmia (57).
Many of the deaths occurred with anesthesia/sedation (often with
cardiac catheterization), suggesting that decreased cardiac output
from anesthetic agents in concert with coronary artery abnormalities altered myocardial perfusion.
A wide variation in the prevalence of systemic hypertension is
shown in Table 1 and is likely due the methodological variations of
the type described in the first paragraph of this section. Although
more commonly found in adults, hypertension can develop during
childhood (58, 59). Three recent studies using 24-hour ambulatory
monitoring found hypertension in 40%–70% of patients (59–61),
though the etiology of hypertension is not fully known and in
most cases is idiopathic. Only a small minority of patients have
overt renovascular disease, such as renal artery stenosis or diffuse
aortic narrowing (47, 58), but all have vascular abnormalities at
the histological level, which will be detailed below.
In one study, infantile hypercalcemia predicted hypertension,
but no relationship was found between blood pressure and
patients reported to be frequently anxious (59). Others have
pointed out that “white coat” hypertension, defined as elevated
office blood pressure but normal ambulatory blood pressure
(62), is frequent in the general pediatric population. Accordingly, it should be considered in WBS before diagnosing bona
fide hypertension, given the high frequency of anxiety disorders
in these individuals. The Coanda effect (the tendency of a jet
stream to adhere to a wall) from SVAS may cause higher blood
pressure only in the right arm (63). Arterial wall thickening seen
with intravascular ultrasound imaging in humans has led to the
hypothesis that decreased compliance of the arterial tree is a factor in hypertension in WBS (64). A later ultrasound study of the
common carotid in 21 patients with WBS confirmed increased
intima-media thickness but found no difference in compliance
compared with controls (65).
The Journal of Clinical Investigation

Other cardiac defects are occasionally observed in WBS. Ventricular septal defects, typically small, were found in 0%–14%
of the series described in Table 1. Single cases of more complex
defects such as tetralogy of Fallot (malalignment ventricular septal
defect with right ventricular outflow obstruction) and atrioventricular canal are reported (40, 66). Mild left ventricular myocardial abnormalities in young patients with WBS in the absence of
clinically significant outflow tract obstruction (67) parallels the
mouse model findings (68). Cerebral arterial disease with stroke
are described infrequently in WBS (69, 70), but the true frequency
of intracranial vascular stenoses is not known.
Vascular pathology
Arterial abnormalities in WBS include localized or diffuse narrowing of elastic arteries. Diagnostic imaging (64, 71) and pathological
studies (72, 73) have both demonstrated generalized arterial wall
thickening even in nonstenotic regions of the arterial tree (Figure
4). These nonstenotic areas are characterized by an expansion of
the media, caused by up to a 2.5-fold increased number of lamellar
units (72), with relatively preserved organization of elastic lamellae
and smooth muscle cells.
Three morphological types of SVAS are defined (74). Membranous SVAS is rare and consists of constricting semicircular valvelike membrane or membranes located at the sinotubular junction.
The membrane contains small stellate cells in abundant mucopolysaccharide ground substance with few collagen and elastic fibrils
but no medial elements (75). The second and third types of SVAS,
the hourglass and diffuse types, share histological characteristics
of disorganized lamellar architecture in the media, haphazard and
fragmented elastic fibers, and focal clumping and hypertrophy of
smooth muscle cells (Figure 4D) (75). In addition, enlargement of
vasa vasorum has also been observed in the media and adventitia.
Focal mural induration is sometimes observed. These regions, in

Figure 3
Aortogram in a 4-year-old individual with WBS. SVAS (arrowhead) and
mild narrowing of the proximal left main coronary artery (arrow) are
shown. The gradient measured at catheterization was 40 mmHg.
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Figure 4
Vascular abnormalities in WBS and in animal models of elastin deficiency. Aortic sections from a 2-year-old healthy donor (A and C) and from
an age-matched WBS patient with severe SVAS (B, D, and E) were stained with Movat’s pentachrome stain to visualize elastic lamellae (black).
A nonstenotic segment of the WBS aorta shows relatively preserved lamellar architecture but greatly increased medial thickness (B). In the
stenotic region, the lamellae in the media are fragmented (D) and a focal area of proliferation is observed on the intimal aspect of the vessel that
accompanies some SVAS lesions, particularly those of the hourglass type (E). Original magnification, ×100 (A and B); ×400 (C–E). Reproduced
from American Journal of Human Genetics (73). Mice heterozygous for targeted inactivation of Eln (+/–) show increased number and decreased
thickness of lamellae (G and I) compared with control (+/+) (F and H). Reproduced from ref. 68. Knockout mice rescued by a human bacterial
artificial chromosome transgene (–/–BAC) (K) have only 30% of normal levels of elastin in the aorta, but thickness of the media is significantly
increased relative to control (J). Reproduced with permission from Circulation Research (81). Complete loss of elastin in homozygous knockout
mice (–/–) (M) show neonatal obstructive disease of the aorta. Control aorta at postnatal day 0.5 shows robust elastin staining (L). Reproduced
with permission from Nature (80).

addition to smooth muscle cells, have an extracellular matrix (Figure 4E) that is rich in mucopolysaccharides and contains endothelium-lined lacunae (74, 75).
Elastin haploinsufficiency as a cause of CV disease
Familial SVAS and WBS. As introduced earlier, understanding of
the molecular basis of CV disease in WBS was aided by studies of
a related but genetically distinct disease, familial SVAS (76). The
spectrum, natural history, and pathological characteristics of
CV and connective tissue lesions in patients with familial SVAS
are virtually identical to those found in WBS. However, familial
SVAS patients do not have neurobehavioral, metabolic, endocrine,
developmental, or some of the craniofacial characteristics of WBS.
These differences are due to the fact that familial SVAS is not a
microdeletion syndrome but rather is caused by translocations
(15), deletions (6, 16), and point mutations (77–79) that disrupt
only the ELN gene. Despite significant allelic heterogeneity, all
1610
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ELN mutations in familial SVAS studied to date cause loss of function at various levels of elastin biosynthesis, most commonly by
eliminating the mutant mRNA via the nonsense-mediated decay
pathway (79). Heterozygous loss-of-function mutations in familial SVAS and chromosomal deletion in WBS both cause reduced
elastin synthesis and increased proliferation of cultured vascular
smooth muscle cells and fibroblasts (73). Thus, both the clinical
characteristics of, and the molecular mechanisms underlying, CV
disease in WBS and familial SVAS appear to be the same and can
be denoted by the term elastin arteriopathy (11).
Animal models. Animal models provide further evidence for elastin
haploinsufficiency as the main cause of CV disease in WBS. Mice
homozygous for targeted inactivation of Eln die from vascular occlusion (Figure 4M) associated with increased subendothelial smooth
muscle cell proliferation in early postnatal life (80). Heterozygous
Eln knockout mice have hypertension, increased arterial stiffness,
and increased number of lamellar units (Figures 4, G and I), but
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Figure 5
Proposed mechanisms of elastin signaling. (A) A 67-kDa EBP is thought to form a receptor complex with protective protein/cathepsin A (PP) and
transmembrane sialidase/neuraminidase (Sase). Elastin peptide binding to the receptor activates the L-type Ca2+ channel and G-proteins (Gα,
β, γ) to activate the MAPK pathway (92). (B) A different pathway postulates a GPCR for tropoelastin. GPCR-elastin binding depresses cAMP
levels by inhibiting adenylate cyclase (AC) and leads to increased actin polymerization through the Rho kinase pathway (87). (C) Cells can also
sense the elastin content indirectly by binding to elastic fiber components such as fibrillins and fibulin-5 via integrins.

thinner vessel walls than wild-type mice (72). Hypertension in
Eln+/– mice is thought to be a developmental adaptation to maintain
vascular caliber and perfusion, whereas the increased number of
lamellar units are believed to normalize vessel wall strain (68). Both
hypertension and increased number of lamellae are characteristic
of the human and the animal model elastin arteriopathy. However,
Eln+/– mice do not develop segmental stenoses of the arteries, and
the media is thinner than in wild-type animals — clear differences
from the human disease. Hypertension in Eln+/– mice is associated
with elevated renin levels and can be blocked by the administration
of angiotensin II receptor blockers candesartan and salarasin (68).
Transgenic expression of elastin rescues perinatal lethality in
Eln–/– mice (Figure 4K) and improves hypertension and decreases
vascular compliance in Eln+/– mice (81). These findings raise the
possibility that upregulation of elastin at the appropriate developmental stage may be a potential strategy to prevent elastin arteriopathy. However, it is unknown whether upregulation of elastin
in already diseased blood vessels (e.g., those that have developed
arteriopathy) can be an effective treatment option.
Modifying factors
The expression of CV disease in WBS is highly variable, ranging from infantile lethality to no overt or clinically apparent CV
involvement. Male sex, a known significant risk factor, is associated with earlier onset and more severe disease (82) but does not
explain all of the variability in CV disease expression. Among
potential genetic modifiers, variants in ELN, in the size of the WBS
critical region, in the “intact” alleles on the normal chromosome 7
homolog, and elsewhere in the genome need to be considered.
Given that the developing vasculature is exquisitely sensitive to
elastin dose (81), factors that influence elastin biosynthesis, including polymorphisms within ELN, are likely to have important effects
on disease severity. Significant differences in elastin synthesis and
cross-linking have been observed between different ethnic groups
(83) suggesting a genetic basis for natural variation in elastin production. Expression of ELN has been studied in two WBS cohorts. One,
enrolling only WBS patients with severe SVAS (73), found significantly reduced ELN expression compared with controls even after
accounting for hemizygosity. In contrast, the second study detected
normal ELN expression on average, though the authors noted high
individual variability (84). Additionally, the second cohort showed
a trend for higher ELN expression in patients without SVAS, but
the difference did not reach statistical significance. These findings
suggest that residual elastin expression protects against the developThe Journal of Clinical Investigation

ment of CV disease in WBS, but adequately powered and controlled
studies are needed to prove this point beyond doubt. Investigation
of patients with intracranial aneurysms identified noncoding polymorphisms that affected the expression of ELN, identifying candidate risk alleles for elastin arteriopathy (85).
Reduced expression of a few nondeleted genes mapping to the
duplicons flanking the WBS critical region have been documented
(84). Variations in the expression of these adjacent genes may be
another factor contributing to the phenotypic differences in individuals with WBS.
Among the genes within the WBS critical region, NCF1 dose
has been associated with the prevalence of hypertension (18). The
NCF1 gene (Figure 2) and two NCF1 pseudogenes, both inactivated
by a GT dinucleotide deletion, are located in a telomeric block of
low copy number repeats flanking the WBS critical region. In the
general population, gene conversion events between the gene and
the pseudogenes result in a natural variation of active NCF1 gene
dose, ranging from 2 to 4 (86). In WBS patients, the deletion breakpoint determines whether the NCF1 gene is deleted (14), so that
gene dose ranges from 1 to 4. In the WBS patients with more than
one copy of NCF1, approximately 56% of the total WBS population, the risk of hypertension is increased 4-fold compared with
those with only one functional NCF1 allele (18). NCF1 encodes the
p47phox subunit of the NADPH oxidase, and reduced angiotensin
II–mediated oxidative stress in the vasculature is proposed as the
mechanism responsible for this protective effect.
Mechanisms of obstructive vascular disease in WBS
Both human and animal studies suggest that elastin is required
for the terminal differentiation and quiescence of vascular smooth
muscle cells. In elastin-null mice, increased vascular smooth muscle cell proliferation both in vivo and in organ culture occur (80).
This hyperproliferative phenotype was associated with decreased
stress fiber and focal adhesion formation and increased vascular
smooth muscle cell migration in vitro and was suppressed by treatment with tropoelastin, the soluble precursor protein of elastin
(87). Similarly, both dermal fibroblasts and aortic smooth muscle
cells isolated from patients with WBS or familial SVAS showed
increased proliferation inversely proportional to the amount of
elastin produced. Treatment of these cells with insoluble elastin
normalized the hyperproliferative phenotype (73).
The formation of segmental obstructive lesions is thought to be a
two-step process, consisting of increased number of lamellar units
and vessel wall thickening during fetal development, leading to a
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uniformly altered vascular tree, followed by postnatal injury-mediated inward remodeling (72). The preferential localization of segmental stenoses to the sinotubular junction and to branch points, areas
of high turbulence, supports this notion. Interestingly, Eln+/– mice
are protected from vascular remodeling following carotid artery
ligation in the ipsilateral vessel while enhanced remodeling occurs
in the contralateral artery (88), suggesting that elastin haploinsufficiency may differentially affect ligation-mediated and flow-mediated injury responses. Eln+/– mice show the same CV remodeling
response in the renal artery clipping model of adult hypertension
as do wild-type animals (89) but are protected from the age-related
vessel wall thickening observed in wild-type animals (90). Further
clinical studies are needed to determine whether patients with WBS
are also protected from age-related vascular changes.
Although it is clear that elastin is a negative regulator of cell
proliferation in development, the precise receptors and pathways
mediating elastin signaling remain to be identified. Studies in different experimental systems yielded conflicting results. A specific
67-kD elastin-binding protein (EBP) localized to the cell surface has
been identified as an enzymatically inactive, alternatively spliced
isoform of β-galactosidase (91). EBP has been shown to mediate
either increased (92) or decreased (93) cell proliferation depending on whether elastin is present in solution or in solid phase.
Elastin peptides were shown to increase the proliferation of coronary artery smooth muscle cells by activating cellular Ca2+ influx
through L-type Ca2+ channels and by activating the focal adhesion
kinase (FAK), Src, and MAPK pathways (92) (Figure 5A). In contrast, canine coronary vascular cells plated on elastin under cyclic
stretch conditions showed reduced serum-induced cell proliferation when compared with cells plated on collagen in an EBP-dependent manner (93). Other studies implicated a GPCR in transmitting elastin signals in elastin-null cells (87). This pathway involves
the inhibition of adenylate cyclase and the activation of RhoA and
Rho kinase, leading to increased actin polymerization (Figure 5B).
Several structural proteins of the elastic fibers including fibrillin-1, fibrillin-2, and fibulin-5 have RGD sequences that serve as
attachment sites for cellular integrins and could provide indirect elastin-dependent signals in the arterial wall (21) (Figure
5C). Interestingly, patients with recessive mutations in fibulin-5
develop SVAS (94) and fibulin-5–null mice show exaggerated
neointima formation, as well as increased vascular cell proliferation and migration (88), providing in vivo evidence to support a
role for fibulin-5 in elastin signaling. Better understanding of the
pathways that connect elastin deficiency to increased vascular cell
proliferation may help identify new targets for the treatment of
CV disease in WBS.
Current treatment
The series from Table 1 describe operative or catheter-based
interventions in 18% of patients for left ventricular outflow tract
obstruction and in 4% of patients for right ventricular outflow
tract obstruction (36–44). Patients with mild SVAS in infancy
(peak catheterization gradient <20 mmHg) often remain stable
and do not require intervention (36).
Operative techniques for repair of SVAS have utilized patch
aortoplasty that may involve augmentation of 1–3 of the aortic
sinuses (95, 96). The symmetric inverted 3-sinus patch plasty has
resulted in improved outcome in one large series (49). Early mortality for repair of SVAS is 1%–9% (range of median or mean age at
operation, 6–16 years), with 20-year survival of 77%–97% and long1612

The Journal of Clinical Investigation

term reduction in peak catheterization gradients in the majority of
patients (36, 49, 95, 97). Although gradients maybe relieved, hypoplasia may persist in the remainder of the aortic arch (98). Diffuse hypoplasia of the aorta is a risk factor for reoperation (36, 49,
99). In patients with severe left main coronary obstruction, patch
enlargement of the coronary os, excision of a fused aortic leaflet,
and bypass grafting have been utilized (100).
Most patients with pulmonary arterial stenosis without significant SVAS can be observed without need for treatment in view of
well-documented spontaneous improvement. For patients with
persistent systemic or suprasystemic right ventricular pressure,
marked asymmetry in pulmonary blood flow, or symptoms, balloon dilation angioplasty has been used to improve arterial diameter, especially in distal vessels. After catheter-based therapy, right
ventricular pressure often remains elevated due to residual proximal obstruction, and the incidence of aneurysms is higher in comparison with non-WBS subjects (101). Patients with biventricular
outflow obstruction with an indication for surgical relief of SVAS
may undergo balloon angioplasty of pulmonary arterial stenosis
prior to surgery. In a series of 33 patients with median age of operation of 4 years for biventricular obstruction, early mortality was
18% (96). Patients with middle aortic syndrome and long segment
narrowing may undergo aorto-aortic bypass or patch plasty with
bypass grafting of involved renal and visceral arteries (102). Catheter-based therapy is an option for some middle aortic lesions that
are more localized (102).
Many patients require treatment for hypertension, but data are
not available to recommend drug selection targeted for WBS. Beta
blocker and calcium channel blocker drugs have been utilized frequently in several of the retrospective series (7, 40, 61, 103), and the
link between infantile hypercalcemia and hypertension (59) suggests
a role for calcium channel blockade. Angiotensin receptor blockade
is effective in the Eln+/– mouse model. Medical treatment in WBS can
be challenging so that multidrug regimens may be required for adequate control of blood pressure. Patients with hypertension resistant to drug therapy should be studied for a renovascular etiology.
Future therapies
Surgical treatment of vascular lesions in WBS frequently relies on the
use of vascular grafts, most commonly made of artificial materials
such as polyethylene terephthalate (Dacron) or expanded polytetrafluoroethylene (ePTFE). The resilience, long-term stability, and cellular attachment properties of elastin make it an attractive material
to explore (104). Elastin-like polymers from recombinant tropoelastin or synthetic elastin peptides can be used to coat or functionalize
graft materials or used as a scaffold for vascular cells in tissue engineering approaches. Coating of synthetic materials with elastin peptides was shown to decrease thrombogenicity in a variety of settings
(105), and insoluble elastin coating significantly decreased in-stent
restenosis (87) in a porcine carotid artery model. Tissue-engineered
aortic grafts prepared using autologous endothelial and smooth
muscle cells seeded onto biodegradable scaffolds and surrounded
with intestinal submucosa showed promising long-term patency in
animal models, but achieving appropriate amounts of elastin formation continues to be a limitation (106).
An alternative approach to the treatment of CV disease in WBS
would involve small molecules or biologicals that can either promote elastin biosynthesis or suppress vascular smooth muscle cell
proliferation and migration. Minoxidil, a K+-channel blocker and
putative NO agonist (107), glucocorticoids (108), and retinoids

http://www.jci.org

Volume 118

Number 5

May 2008

Downloaded on August 16, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/35309

science in medicine
(109) have been shown to upregulate elastin production in vivo.
MMP inhibitors may be beneficial in preventing elastin degradation associated with vascular remodeling (110). A number of pulmonary vasodilatory drugs are efficacious in the treatment of primary pulmonary arterial hypertension, including calcium channel
blockers, prostacyclin analogs, endothelin receptor antagonists,
and NO agonists (111, 112). These agents could be evaluated as
potential modulators of vascular lesions in WBS, even though the
pathology of ELN arteriopathy is distinct from primary pulmonary arterial hypertension.
Nutritional intervention or nutraceuticals may theoretically
be targets affecting elastin arteriopathy. Copper deficiency (113),
β-aminopropionitrile (contained in certain legumes), and drugs
such as amine oxidase inhibitors and penicillamine (114) all interfere with the activity of lysyl oxidases, a family of enzymes required
for elastin cross-linking (115). On the other hand, dill extract has
been shown to increase LOXL1 (lysyl oxidase like 1) gene expression
and elastin deposition in vitro (116). Finally, ellagic and tannic acid
(polyphenols found in berries and nuts) inhibit proteolytic degradation of elastin and increase elastin deposition in skin fibroblast and
organ cultures (117). It remains to be shown whether any of these
natural products can reverse the effects of elastin deficiency in vivo.
Better understanding of the mechanisms behind the spontaneous improvement of pulmonary vascular lesions in WBS might lead
to new treatment options. Developmental, physiological, mechanical, and biochemical differences between the pulmonary and systemic arterial trees need to be considered as potential mechanisms.
Benign peripheral pulmonary stenosis is a common cause of innocent murmurs detected in the first month of life. The murmur and
slightly elevated flow velocity are usually gone by 6–12 months
of life (118, 119). Neonatal adaptation to breathing is known to
involve a rapid increase in pulmonary flow, with a more gradual
growth of the branch pulmonary arteries. One can speculate that
this developmental adaptation may account for some of the resolution of pulmonary stenotic lesions in infants with WBS.
Another potential therapeutic strategy involves targeted
upregulation of a patient’s own genes, as has already been accomplished for HIF-1α in a patient with peripheral artery disease
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